AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

NASDAQ:ORPNBioblast Pharma Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$11.50
+6.21 (+117.39 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$11.50
Now: $11.50
$11.50
50-Day Range
$11.50
MA: $19.65
$28.49
52-Week Range
$6.16
Now: $11.50
$30.00
VolumeN/A
Average VolumeN/A
Market Capitalization$4.83 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Its product candidate is Trehalose intravenous 90mg/mL solution, a protein stabilizer and autophagy enhancer for the treatment of patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. The company has a collaboration with Team Sanfilippo to evaluate Trehalose for the treatment of sanfilippo syndrome. Bioblast Pharma Ltd. was founded in 2012 and is headquartered in Tel Aviv, Israel.
Read More
Bioblast Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.64 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORPN
CUSIPN/A
Phone972-3573-6632

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$7.56 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$4.83 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ORPN News and Ratings via Email

Sign-up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter.

Bioblast Pharma (NASDAQ:ORPN) Frequently Asked Questions

When did Bioblast Pharma's stock split? How did Bioblast Pharma's stock split work?

Bioblast Pharma shares reverse split on Wednesday, March 6th 2019. The 1-8 reverse split was announced on Wednesday, March 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 5th 2019. An investor that had 100 shares of Bioblast Pharma stock prior to the reverse split would have 13 shares after the split.

Has Bioblast Pharma been receiving favorable news coverage?

News headlines about ORPN stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bioblast Pharma earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Bioblast Pharma.

Who are some of Bioblast Pharma's key competitors?

What other stocks do shareholders of Bioblast Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bioblast Pharma investors own include Synergy Pharmaceuticals (SGYP), Inovio Pharmaceuticals (INO), Immunomedics (IMMU), SLS International (SLS), Verastem (VSTM), Voyager Therapeutics (VYGR), Athersys (ATHX), ContraFect (CFRX), CTI BioPharma (CTIC) and Eleven Biotherapeutics (EBIO).

Who are Bioblast Pharma's key executives?

Bioblast Pharma's management team includes the following people:
  • Dr. Dalia Megiddo M.B.A., Ph.D., M.D., MBA, Co-Founder, MD, CEO & Director (Age 67)
  • Dr. Warren W. Wasiewski, VP of R&D (Age 67)
  • Prof. Avizohar Argov M.D., Special Medical Advisor to the Chief Exec. Officer and Member of Scientific Advisory Board (Age 72)

What is Bioblast Pharma's stock symbol?

Bioblast Pharma trades on the NASDAQ under the ticker symbol "ORPN."

What is Bioblast Pharma's stock price today?

One share of ORPN stock can currently be purchased for approximately $11.50.

How big of a company is Bioblast Pharma?

Bioblast Pharma has a market capitalization of $4.83 million.

What is Bioblast Pharma's official website?

The official website for Bioblast Pharma is bioblastpharma.com.

How can I contact Bioblast Pharma?

Bioblast Pharma's mailing address is PO Box 318, Tel-Aviv Is, 6100201. The biopharmaceutical company can be reached via phone at 972-3573-6632 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.